VP4/VP56/VP35 Virus-like Particles Effectively Protect Grass Carp (Ctenopharyngodon idella) against GCRV-II Infection
Author:
Tian Qingqing12, Huo Xingchen1, Liu Qian1, Yang Chunrong3, Zhang Yongan1, Su Jianguo12ORCID
Affiliation:
1. Hubei Hongshan Laboratory, College of Fisheries, Huazhong Agricultural University, Wuhan 430070, China 2. Laboratory for Marine Biology and Biotechnology, Pilot National Laboratory for Marine Science and Technology, Qingdao 266237, China 3. College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430000, China
Abstract
Grass carp reovirus (GCRV) seriously threatens the grass carp (Ctenopharyngodon idella) industry. Prophylactic GCRV vaccines prepared by virus-like particle (VLP) assembly biotechnology can improve effectiveness and safety. The highly immunogenic candidate antigens of GCRV vaccines that have been generally considered are the outer capsid proteins VP4, VP56, and VP35. In this study, VP4, VP56, and VP35 were expressed in an Escherichia coli expression system and a Pichia pastoris expression system. The successful assembly of uniform, stable, and non-toxic VP4/VP56/VP35 VLPs was confirmed through various assays. After vaccination and GCRV infection, the survival rate in the VLPs + adjuvant Astragalus polysaccharide (APS) group was the highest (62%), 40% higher than that in control group (22%). Through the antibody levels, tissue viral load, and antioxidant immunity assays, the P. pastoris VLP vaccine effectively improved IgM levels, alleviated tissue virus load, and regulated antioxidant immune-related indicators. The treatment with P. pastoris VLPs enhanced the mRNA expression of important immune-related genes in the head kidney, as measured by qRT-PCR assay. Upon hematoxylin-eosin staining examination, relatively reduced tissue pathological damage was observed in the VLPs + APS group. The novel vaccine using P. pastoris VLPs as an effective green biological agent provides a prospective strategy for the control of fish viral diseases.
Funder
National Natural Science Foundation of China
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference51 articles.
1. Gao, T., Gao, C., Wu, S., Wang, Y., Yin, J., Li, Y., Zeng, W., Bergmann, S.M., and Wang, Q. (2021). Recombinant baculovirus-produced grass carp reovirus virus-like particles as vaccine candidate that provides protective immunity against GCRV genotype II infection in grass carp. Vaccines, 9. 2. Artificial substrata increase pond farming density of grass carp (Ctenopharyngodon idella) by increasing the bacteria that participate in nitrogen and phosphorus cycles in pond water;Li;PeerJ,2019 3. He, L., Zhang, A., Pei, Y., Chu, P., Li, Y., Huang, R., Liao, L., Zhu, Z., and Wang, Y. (2017). Differences in responses of grass carp to different types of grass carp reovirus (GCRV) and the mechanism of hemorrhage revealed by transcriptome sequencing. BMC Genom., 18. 4. Oral Lactobacillus casei expressing VP56310–500 and adjuvant flagellin C delivered by alginate-chitosan microcapsules remarkably enhances the immune protection against GCRV infection in grass carp;Chang;Aquaculture,2023 5. Dual-targeting polymer nanoparticles efficiently deliver DNA vaccine and induce robust prophylactic immunity against spring viremia of carp virus infection;Zhang;Microbiol. Spectr.,2022
|
|